Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Oppenheimer

Keros Therapeutics (NASDAQ:KROS) had its price target decreased by Oppenheimer from $63.00 to $23.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective points to a potential upside of 125.51% from the company’s current price.

Other research analysts also recently issued reports about the company. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. HC Wainwright dropped their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Scotiabank decreased their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research report on Friday, December 13th. Finally, Guggenheim cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $70.56.

Keros Therapeutics Trading Down 2.1 %

Shares of KROS stock traded down $0.22 during trading hours on Thursday, hitting $10.20. The company’s stock had a trading volume of 1,444,360 shares, compared to its average volume of 2,387,313. The company has a 50 day moving average of $39.77 and a 200 day moving average of $47.88. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The stock has a market cap of $413.16 million, a PE ratio of -1.96 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.33) earnings per share. As a group, analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently bought and sold shares of KROS. Geode Capital Management LLC lifted its position in shares of Keros Therapeutics by 6.8% in the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after acquiring an additional 46,041 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after purchasing an additional 32,492 shares in the last quarter. Barclays PLC boosted its stake in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Keros Therapeutics during the third quarter worth $603,000. Finally, Point72 Asset Management L.P. raised its position in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.